Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Memantine Antidementia Drug Poses Higher Pneumonia Risk

By University of Eastern Finland | November 25, 2016

A recent study from the University of Eastern Finland shows that among users of antidementia drugs, persons using memantine have the highest risk of pneumonia. The use of rivastigmine patches is associated with an increased risk as well.

The study found that persons using donepezil or galantamine had the lowest risk of pneumonia. However, persons using memantine or rivastigmine patches had a 1.6 and 1.15 times higher risk of pneumonia, respectively, but no elevated risk was observed among patients using rivastigmine in capsule form. The real risk increase may be even higher, as only cases of pneumonia leading to hospitalization or death were taken into account.

The study is the first to compare the risk of pneumonia associated with different antidementia drugs and drug forms. The results are not likely to be explained by differences between drug molecules, as rivastigmine was associated with an increased risk of pneumonia in patch form only. The increased pneumonia risk among persons using memantine or rivastigmine patches may be explained at least partly by the fact that these medications are often used in more advanced states of dementia. However, all participants were home-dwelling persons.

The study is based on data from a nationwide register-based study (MEDALZ) conducted at the University of Eastern Finland. The risk of pneumonia was compared among users of different antidementia drugs. The study population consisted of 65,481 persons diagnosed with Alzheimer’s disease during 2005-2011 in Finland.

No cure for Alzheimer’s diseases currently exists, but the progression of the disease can be slowed down by antidementia drugs, such as memantine and acetylcholinesterase inhibitors such as donepezil, galantamine, and rivastigmine. Persons with Alzheimer’s disease have an elevated risk of pneumonia, and it is one of the most common causes of hospitalization among persons with Alzheimer’s disease. Pneumonia is also a common cause of death in this population.

The findings published in the Annals of Medicine. In addition to researchers from the University of Eastern Finland, also researchers from the University of Turku and Karolinska Institutet participated in the study.

(Source: AlphaGalileo)


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE